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Abstract
Summary Compliance and persistence with daily, weekly, and
monthly bisphosphonates (BPs) for osteoporosis were
assessed using data from the Platform for Clinical
Information Statistical Analysis (CISA) database that contains
data of prescriptions in 13 university hospitals in Japan. The
analysis revealed compliance and persistence improved as the
dosing interval increases.
Purpose BPs are an effective first-line therapy for osteoporo-
sis, but adherence is low. Compliance (medication possession
ratio, MPR) and persistence (time to discontinuation) with
daily, weekly, and monthly BPs were compared to ensure
better adherence.
Methods Using data from the CISA database containing pre-
scription data in 13 university hospitals in Japan, adherence to
oral BPs of osteoporotic patients was investigated. Daily and
weekly BPs were compared for compliance and persistence
over 5 and 8 years, and daily, weekly, and monthly BPs for
those over 1 and 2 years.
Results MPR over 5 years was 20.8 and 60.9 % for daily
and weekly BPs (p<0.001), respectively. MPR over 1 year
was 38.6, 70.6, and 77.7 % for daily, weekly, and monthly
BPs (P<0.001), respectively. Persistence over 8 years was
significantly higher in weekly than daily BPs (p<0.001),
and that over 5 years was highest in patients receiving
BPs monthly (p<0.01).
Conclusion The present analysis indicates that a monthly reg-
imen has better adherence to treatment as compared with
weekly and daily regimens.
Keywords Adherence . Bisphosphonate . Compliance .
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Introduction
Bisphosphonates (BPs) are an effective first-line therapy for
the treatment of osteoporosis, but adherence to therapy could
be lower than other drugs for the treatment of chronic diseases
with the exception of gout treatment and others [1, 2]. The
poor adherence to BP therapy has been related to the complex-
ity of required dosing procedures and the severity of possible
adverse drug reactions. As poor adherence to BP therapy has
been reported to increase the risk of osteoporotic fractures [3,
4], better adherence must be ensured to continue treatment.
As a wide variety of BP products including those for daily,
weekly, and monthly oral dosing, and those for monthly intra-
venous injection/infusion have been launched in Japan, phy-
sicians are able to select from diverse options to ensure better
adherence to BP therapy. Although reports in Japan and other
countries [5–7] have suggested better adherence with monthly
than weekly dosing, there have been no published analyses
using prescription databases in Japan.
Adherence to treatment is generally expressed with com-
pliance, which is calculated as medication possession ratio
(MPR), and persistence, which is defined as time to discon-
tinuation [8]. In the present study, we used data from the
Platform for Clinical Information Statistical Analysis (CISA)
database that contains data of prescriptions in 13 university
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hospitals in Japan (http://www.cisa.jp) to calculate
compliance (MPR) and persistence with oral BPs with differ-
ent dosing intervals in osteoporotic patients.
Patients and methods
Data from the CISA database were used to investigate ad-
herence with oral BP therapy in patients with osteoporosis.
Drug dispensing data at the individual level were retrieved
from the CISA database, which contains substantial clinical
information obtained in Japan. Data from CISA are provid-
ed in a fully anonymized form to 13 national university
hospitals in this study. In the CISA database, each prescrip-
tion record contains basic patient characteristics (anony-
mous identifier, gender, and date of birth) and information
on the drug name, anatomical therapeutic chemical code,
dosage, and dispensing date. Osteoporosis was diagnosed
by Japanese guidelines which included the data of BMD,
fracture history, and other risk factors [9].
Adherence to BP therapy was assessed with compliance
and persistence. Compliance was measured with MPR, which
was calculated by dividing the duration of prescription by the
duration of observation. Persistence was calculated as the ratio
of patients receiving BP therapy to patients prescribed with
BPs at each time point. According to a previous report [6], a
limit on the number of days allowed between refills, the per-
missible gap, was specified as 30, 30, and 45 days for daily,
weekly, and monthly BPs, respectively [6] and 90 days for all
in additional analysis [10].
Compliance
Data of 12,230 patients who were newly prescribed with
oral BPs during the period between April 2006 and August
2008 were assessed for MPR over 5 years (Table 1). The
patients consisted of 4178 and 8052 patients receiving BPs
daily and weekly, and 2353 men and 9877 women. The
mean age was 59.8 years.
Since oral BPs for monthly dosing were launched in
September 2011, and became available in the 13 university
hospitals in November 2011, a comparison of daily, weekly,
and monthly BPs was made using data of 5039 patients who
were newly prescribed with BPs during the period between
November 2011 and January 2013 by calculating MPR over
1 year of daily, weekly, and monthly BPs. These patients con-
sist of 242, 2516, and 2281 patients receiving BPs daily,
weekly, and monthly, and 1150 men and 3889 women. The
mean age was 62.0 years.
Persistence
Persistence over 8 years was calculated using data from 21,
972 ambulatory patients who were newly prescribed with oral
BPs during the period from April 2006 to January 2014
(Table 1). These patients consisted of 6768 and 15,204 pa-
tients receiving BPs daily and weekly, and 4751 men and
17,221 women. The mean age was 60.8 years.
A comparison of persistence over 2 years with daily, week-
ly, and monthly BPs was made using data from 9326 ambu-
latory patients who were newly prescribed with oral BPs dur-
ing the period from November 2011 to January 2014. Patients
consisted of 396, 4392, and 4538 patients receiving BPs daily,
weekly, and monthly, and 2066 men and 7260 women. The
mean age was 62.2 years.
Statistical analysis
Analyses in the present study were conducted in the CISA
data center. The significance of the difference in MPR be-
tween two groups was tested using the Wilcoxon test, a
non-parametric test, and that among three groups was tested
using the Kruskal-Wallis test followed by the Bonferroni
test to compare all pairs of the three groups. The persistent
curve was estimated using the Kaplan-Meier method. The
log-rank test was used to compare persistence between
groups. All analyses were conducted using the statistical
package R, version 3.1.2.
Table 1 Baseline characteristics of subjects
Compliance (MPR) Persistence
Observation period 5 years 1 year 8 years 2 years
Date of first prescription Apr 2006–Aug 2008 Nov 2011–Jan 2013 Apr 2006–Jan 2014 Nov 2011–Jan 2014
Daily 4178 242 6768 396
Weekly 8052 2516 15,204 4392
Monthly – 2281 – 4538
Oral BPs for daily, weekly, and monthly dosing were launched in August 2001, September 2006, and September 2011, respectively
MPR medication possession ratio
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Results
Compliance
In 12,230 ambulatory patients who were newly prescribed
with daily or weekly oral BP therapy during the period from
April 2006 to August 2008, MPR over 5 years was 20.8 and
60.9 % for patients receiving BPs daily and weekly, respec-
tively (p<0.001) (Table 2).
MPR over 1 year in 5039 patients newly prescribed with
daily, weekly, and monthly BP therapy from November 2011
to January 2013 was 38.6, 70.6, and 77.7 % in patients receiv-
ing the drug daily, weekly and monthly, respectively
(p<0.001). MPR was highest in patients receiving BPs
monthly (Table 2).
Persistence
Figures 1 and 2 illustrate persistence over 8 years with daily
and weekly BP therapy in 21,972 ambulatory patients who
were newly prescribed with daily or weekly oral BP therapy
during the period between April 2006 and January 2014.
Persistence with permissible gaps of 30 and 90 days was sig-
nificantly higher in patients receiving weekly than daily BP
therapy at all time points (p<0.001).
A comparison of persistence over 2 years with the three
different dosing intervals in 9326 patients newly prescribed
with oral BP therapy from November 2011 to January 2014
revealed that persistence was significantly higher in patients
receiving BPs monthly throughout the 2-year period
(p<0.001) (Fig. 3). In an additional analysis using a permis-
sible gap of 90 days, the persistence curve was shown with the
same pattern as in Fig. 3 (Fig. 4).
Discussion
Currently, a wide variety of BP products have been developed
and are available in the clinical setting. Physicians are able to
select from daily, weekly, or monthly oral therapy, or monthly
intravenous injection/infusion to improve adherence to BP
therapy. In the present study, we were able to calculate MPR
over 5 years and persistence over 8 years to investigate the
relationship between dosing interval of oral BPs and adher-
ence to BP therapy in osteoporotic patients.
In previous studies where two dosing intervals of BPs were
compared in Japan and other countries [5–7, 10–18], weekly
and monthly regimens were superior to daily and weekly reg-
imens, respectively, in terms of adherence. In the present study
where daily, weekly, andmonthly oral BP therapies were com-
pared, adherence increased as the dosing interval increased.
Although the better adherence of monthly than week-
ly BPs is generally attributable to the convenience in
using monthly BPs, it has also been reported that week-
ly BPs show persistence superior to monthly BPs [19]
Table 2 Mean MPR (%) for daily, weekly, and monthly BPs
MPR Daily Weekly Monthly p value
5 years 20.8 60.9 – <0.001
1 year 38.6 70.6 77.7 <0.001
MPR medication possession ratio
No. at risk
Weekly 15,204 7,669 4,972 3,170 1,896 973 250 34
Daily 6,768 2,249 878 396 248 155 99 54 18
Fig. 1 Kaplan-Meier analysis of the discontinuation of bisphosphonate
treatment over 8 years (log-rank test; p<0.001). A permissible gap of
30 days was allowed in this analysis
No. at risk
Weekly 15,204 8,704 6,068 4,108 2,656 1,494 453 52
Daily 6,768 2,716 1,156 569 363 225 158 99 19
Fig. 2 Kaplan-Meier analysis of the discontinuation of bisphosphonate
treatment over 8 years (log-rank test; p<0.001). A permissible gap of
90 days was allowed in this analysis
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and that weekly and monthly BPs did not differ signif-
icantly in terms of persistence [20]. Researchers have
pointed out that detailed explanation to the patient about
the fracture prevention effects, possible adverse drug
reactions, and safety of BP therapy is more important
than dosing interval in terms of ensuring persistence
[21–24]. Persistence of BP therapy should be improved
not only through prolonging the dosing interval but
through individualizing the treatment to meet the pa-
tient’s preference and circumstance and thereby motivate
him/her to continue treatment [25–27].
As a difference in the permissible gap may result in differ-
ent findings, an additional analysis using permissible gaps of
90, 90, and 90 days for daily, weekly, and monthly BPs was
conducted in addition to the analysis with 30, 30, and 45 days
according to a previous report [6]. Persistence was also higher
for monthly BPs than daily and weekly BPs in the additional
analysis.
It has been reported that MPR, a measure of compliance,
of BP (alendronate or risedronate) closely correlates with
the incidence of osteoporotic fracture, and that the inci-
dence of fracture decreases substantially in patients with a
MPR of >80 % although no fracture risk reduction was
observed in patients with a MPR of <50 % [4]. As it has
also been reported that for each decrease of the MPR by
1 %, the risk of hip fracture increased by 0.4 % [3], it is
essential to encourage patients to continue treatment as
instructed and maintain a high MPR, i.e., 80 % or higher,
in order to prevent fractures. Compliance to treatment for
osteoporosis is generally low [28]. In order to facilitate
patients to understand the efficacy of treatment and contin-
ue treatment, drugs must exhibit noticeable effects such as
improvement in bone mineral density [29]. In fact, BPs
have favorable effects on bone mineral density that moti-
vate patients to continue treatment. However, compliance
with BP therapy must be improved further, although com-
pliance increases as dosing intervals increase [11]. In the
present study, MPR was highest in patients receiving BPs
monthly, but MPR with monthly regimens over 1 year was
77.7 %, which did not exceed 80 %. Further approaches
should be made to improve compliance [7, 28, 30].
One limitation of this study is that we could not obtain data
on patient’s fracture history, details of examination results, and
communication between healthcare professionals and patients
in the clinical setting, such as explanation about the disease,
from the CISA database we used to obtain prescription data.
We could not assess the effects of communication between
patients and healthcare professionals. Second, as the present
study was conducted in patients who visited university hospi-
tals for the treatment of osteoporosis, the results may not be
generalized to patients treated in other settings. Thirteen na-
tional university hospitals are widely located without geo-
graphical deviation, but these data from CISA are not
expressed for general Japanese data.
In conclusion, adherence with BP therapy was higher in
monthly regimens than in daily and weekly regimens.
Monthly regimens are considered beneficial in improving ad-
herence to oral BPs for osteoporosis treatment.
No. at risk
Monthly 4,538 2,837 1,730 720 397
Weekly 4,392 2,404 1,345 714 270
Daily 396 116 45 26 18
Fig. 3 Kaplan-Meier analysis of the discontinuation of bisphosphonate
treatment over 2 years (log-rank test, p<0.001). A permissible gap of
30 days for daily/weekly and 45 days for monthly was allowed in this
analysis
No. at risk
Monthly 4,538 2,940 1,832 778 454
Weekly 4,392 2,558 1,494 821 333
Daily 396 129 58 31 20
Fig. 4 Kaplan-Meier analysis of the discontinuation of bisphosphonate
treatment over 2 years (log-rank test, p<0.001). A permissible gap of
90 days was allowed in this analysis
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